EP1343819A4 - Hla-a2.1 binding peptides and their uses - Google Patents

Hla-a2.1 binding peptides and their uses

Info

Publication number
EP1343819A4
EP1343819A4 EP00964938A EP00964938A EP1343819A4 EP 1343819 A4 EP1343819 A4 EP 1343819A4 EP 00964938 A EP00964938 A EP 00964938A EP 00964938 A EP00964938 A EP 00964938A EP 1343819 A4 EP1343819 A4 EP 1343819A4
Authority
EP
European Patent Office
Prior art keywords
hla
binding peptides
peptides
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00964938A
Other languages
German (de)
French (fr)
Other versions
EP1343819A1 (en
Inventor
Howard M Grey
Alessandro Sette
John Sidney
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Priority to EP05016493A priority Critical patent/EP1619207A3/en
Publication of EP1343819A1 publication Critical patent/EP1343819A1/en
Publication of EP1343819A4 publication Critical patent/EP1343819A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00964938A 2000-09-01 2000-09-01 Hla-a2.1 binding peptides and their uses Withdrawn EP1343819A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05016493A EP1619207A3 (en) 2000-09-01 2000-09-01 HLA-A2.1 binding peptides derived from HCV and their uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/024102 WO2002020616A1 (en) 2000-09-01 2000-09-01 Hla-a2.1 binding peptides and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP05016493A Division EP1619207A3 (en) 2000-09-01 2000-09-01 HLA-A2.1 binding peptides derived from HCV and their uses

Publications (2)

Publication Number Publication Date
EP1343819A1 EP1343819A1 (en) 2003-09-17
EP1343819A4 true EP1343819A4 (en) 2005-03-23

Family

ID=21741736

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05016493A Withdrawn EP1619207A3 (en) 2000-09-01 2000-09-01 HLA-A2.1 binding peptides derived from HCV and their uses
EP00964938A Withdrawn EP1343819A4 (en) 2000-09-01 2000-09-01 Hla-a2.1 binding peptides and their uses

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05016493A Withdrawn EP1619207A3 (en) 2000-09-01 2000-09-01 HLA-A2.1 binding peptides derived from HCV and their uses

Country Status (5)

Country Link
EP (2) EP1619207A3 (en)
JP (1) JP2004517609A (en)
AU (1) AU2000275748A1 (en)
CA (1) CA2420225A1 (en)
WO (1) WO2002020616A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20050267020A1 (en) * 2001-09-27 2005-12-01 Olivier Faure Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same
AU2003221831A1 (en) * 2002-04-05 2003-10-27 Epimmune Inc. Heteroclitic analogs and related methods
EP2112229A3 (en) 2002-11-25 2009-12-02 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
CA2511775A1 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1,-a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
EP1903056A3 (en) * 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof
WO2006009838A2 (en) * 2004-06-17 2006-01-26 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041440A1 (en) * 1996-04-26 1997-11-06 Rijksuniversiteit Te Leiden Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes
WO1998033888A1 (en) * 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
WO2001036452A2 (en) * 1999-11-18 2001-05-25 Epimmune Inc. Heteroclitic analogs of class i epitodes
WO2001042270A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
WO2001041741A1 (en) * 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2157510A1 (en) * 1993-03-05 1994-09-15 Howard M. Grey Hla-a2.1 binding peptides and their uses
AU702367B2 (en) * 1993-08-02 1999-02-18 Scripps Research Institute, The Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
ATE296313T1 (en) * 1996-03-21 2005-06-15 Epimmune Inc HLA-A2.1 BINDING PEPTIDES AND THEIR USE
ES2265165T3 (en) * 1997-07-10 2007-02-01 Mannkind Corporation DEVICE TO INDUCE AN ANSWER LTC.
CA2377525A1 (en) * 1999-07-19 2001-03-29 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
AT408721B (en) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIG

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041440A1 (en) * 1996-04-26 1997-11-06 Rijksuniversiteit Te Leiden Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes
WO1998033888A1 (en) * 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
WO2001036452A2 (en) * 1999-11-18 2001-05-25 Epimmune Inc. Heteroclitic analogs of class i epitodes
WO2001042270A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
WO2001041741A1 (en) * 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALTERS S E ET AL: "DENDRITIC CELLS PULSED WITH CEA PEPTIDE INDUCE CEA-SPECIFIC CTL WITH RESTRICTED TCR REPERTOIRE", JOURNAL OF IMMUNOTHERAPY, RAVEN PRESS, NEW YORK, US, vol. 21, no. 1, January 1998 (1998-01-01), pages 17 - 26, XP001061479, ISSN: 1524-9557 *
FALK K ET AL: "ALLELE-SPECIFIC MOTIFS REVEALED BY SEQUENCING OF SELF-PEPTIDES ELUTED FROM MHC MOLECULES", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 351, no. 6324, 23 May 1991 (1991-05-23), pages 290 - 296, XP000310533, ISSN: 0028-0836 *
KAWASHIMA I ET AL: "THE MULTI-EPITOPE APPROACH FOR IMMUNOTHERAPY FOR CANCER: IDENTIFICATION OF SEVERAL CTL EPITOPES FROM VARIOUS TUMOR-ASSOCIATED ANTIGENS EXPRESSED ON SOLID EPITHELIAL TUMORS", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 59, no. 1, January 1998 (1998-01-01), pages 1 - 14, XP001012509, ISSN: 0198-8859 *
See also references of WO0220616A1 *
WIZEL BENJAMIN ET AL: "Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses", JOURNAL OF CLINICAL INVESTIGATION, vol. 102, no. 5, 1 September 1998 (1998-09-01), pages 1062 - 1071, XP002285521, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
CA2420225A1 (en) 2002-03-14
AU2000275748A1 (en) 2002-03-22
WO2002020616A1 (en) 2002-03-14
EP1619207A3 (en) 2006-02-08
EP1343819A1 (en) 2003-09-17
JP2004517609A (en) 2004-06-17
EP1619207A2 (en) 2006-01-25

Similar Documents

Publication Publication Date Title
TWI317737B (en) Membrane penetrating peptides and uses thereof
GB0014870D0 (en) Peptides
GB2362604B (en) Book cover and book binding system using the book cover
EP1263775A4 (en) Hla binding peptides and their uses
GB9806806D0 (en) Peptides and uses thereof
IL153539A0 (en) Protein complexes and methods for the preparation thereof
EP1414848A4 (en) Replikin peptides and uses thereof
EP1419175A4 (en) Replikin peptides and uses thereof
EP1343819A4 (en) Hla-a2.1 binding peptides and their uses
IL131707A0 (en) Acetylcholinesterase-derived peptides and uses thereof
GB0029777D0 (en) Peptides
GB0026134D0 (en) Peptides and their use
GB0015761D0 (en) Polypeptide
GB0001825D0 (en) Peptides
EP1313505A4 (en) Hla binding peptides and their uses
GB0121215D0 (en) Polypeptide
AU6534301A (en) Phosphorylated polypeptides and uses related thereto
EP1071434A4 (en) Cnre binding factors and uses thereof
GB0007263D0 (en) Peptides
AU5995701A (en) Synthetic peptides and uses therefore
GB0013239D0 (en) Polypeptide
EP1300416A4 (en) Memory-enhancing peptides and the use thereof
AU4726901A (en) Novel human proteins and polynucleotides encoding the same
AU8557801A (en) Modified proteins, isolated novel peptides, and uses thereof
MXPA03000981A (en) High affinity integrin polypeptides and uses thereof.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 9/90 B

Ipc: 7C 07K 14/18 B

Ipc: 7C 07K 14/16 B

Ipc: 7C 07K 14/11 B

Ipc: 7C 07K 14/08 B

Ipc: 7C 07K 14/03 B

Ipc: 7C 07K 14/02 B

Ipc: 7A 61K 39/00 B

Ipc: 7C 07H 21/04 B

Ipc: 7C 07K 16/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20050202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060404